{"id":"NCT05856227","sponsor":"Basilea Pharmaceutica","briefTitle":"Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age","officialTitle":"A Multicenter, Open-label, Single-arm, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Ceftobiprole Medocaril in Term and Pre-term Neonates and Infants up to 3 Months of Age With Late-onset Sepsis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-08-06","primaryCompletion":"2024-12-18","completion":"2024-12-18","firstPosted":"2023-05-12","resultsPosted":"2025-07-28","lastUpdate":"2025-07-28"},"enrollment":9,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neonatal Sepsis"],"interventions":[{"type":"DRUG","name":"Ceftobiprole medocaril","otherNames":[]}],"arms":[{"label":"Treatment Arm: Ceftobiprole","type":"EXPERIMENTAL"}],"summary":"This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.","primaryOutcome":{"measure":"Number of Patients With Adverse Events (AEs)","timeFrame":"Up to 5-7 weeks","effectByArm":[{"arm":"Pre-term Neonates","deltaMin":3,"sd":null},{"arm":"Term Neonates","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":14,"countries":["United States","Bulgaria","Estonia","Germany","Latvia","Lithuania","Poland","Slovakia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":6},"commonTop":["Oedema","Thrombocytosis","Intraventricular haemorrhage neonatal","Bronchopulmonary dysplasia","Gastrointestinal haemorrhage"]}}